Song, Haiqing
Wang, Yuan
Ma, Qingfeng
Chen, Huisheng
Liu, Bo
Yang, Yi
Zhu, Jianguo
Zhao, Shigang
Jin, Xiaoping
Li, Yongqiu
Wang, Yanyong
Zhu, Runxiu
Zhao, Liandong
Liu, Junyan
Ma, Qilin
Lin, Yongzhong
Tian, Xiangyang
Zhang, Qing
Zhou, Weidong
Zhang, Yongbo
Zhou, Jie
Li, Yansong
Song, Zhi
Feng, Wuwei
Liu, Rui
Ji, Xunming
Wang, Yuping http://orcid.org/0000-0002-6482-9710
Funding for this research was provided by:
tasly biopharmaceuticals co., ltd
Article History
Received: 6 July 2021
Revised: 22 March 2022
Accepted: 22 March 2022
First Online: 3 May 2022
Declarations
:
: The clinical trial was accepted by the National Medical Products Administration (No. 2016L05323) and approved by the institutional review boards of the 23 participating centers. The study was conducted in accordance with the principles of the Declaration of Helsinki.
: Written informed consent was obtained from all patients prior to enrollment.
: Dr Liu R reports being an employee of Tasly Biopharmaceuticals Co.,Ltd,. No other potential conflict of interest relevant to this article was reported.